GWN Securities Inc. Makes New Investment in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

GWN Securities Inc. bought a new position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,970 shares of the company’s stock, valued at approximately $232,000.

Other hedge funds also recently bought and sold shares of the company. Darwin Wealth Management LLC bought a new stake in shares of GE HealthCare Technologies during the 3rd quarter worth about $31,000. Continuum Advisory LLC boosted its stake in shares of GE HealthCare Technologies by 101.8% during the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after acquiring an additional 168 shares in the last quarter. Bank of Jackson Hole Trust bought a new stake in shares of GE HealthCare Technologies during the 4th quarter worth about $32,000. OFI Invest Asset Management bought a new stake in shares of GE HealthCare Technologies during the 4th quarter worth about $34,000. Finally, Avion Wealth boosted its stake in shares of GE HealthCare Technologies by 497.4% during the 4th quarter. Avion Wealth now owns 460 shares of the company’s stock worth $35,000 after acquiring an additional 383 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

GE HealthCare Technologies Price Performance

Shares of GEHC stock opened at $82.47 on Tuesday. The stock has a 50 day moving average of $87.27 and a two-hundred day moving average of $86.12. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88. GE HealthCare Technologies Inc. has a 12 month low of $74.51 and a 12 month high of $94.80. The company has a market capitalization of $37.71 billion, a P/E ratio of 19.05, a P/E/G ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The business had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $5.33 billion. As a group, equities analysts expect that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on GEHC shares. Citigroup upped their price target on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. The Goldman Sachs Group upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and increased their target price for the company from $85.00 to $100.00 in a research note on Tuesday, March 11th. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their target price for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. Finally, Wells Fargo & Company increased their target price on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $98.75.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.